Lazertinib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 179 publications

Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer.

Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer.

Journal: Future oncology (London, England)
Published: August 24, 2026

Scalp and genital ulcerations as cutaneous toxicities of amivantamab and lazertinib combination therapy.

Scalp and genital ulcerations as cutaneous toxicities of amivantamab and lazertinib combination therapy.

Journal: JAAD case reports
Published: July 01, 2026

Correction: Maione et al. Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option? Curr. Oncol. 2026, 33, 54.

Correction: Maione et al. Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option? Curr. Oncol. 2026, 33, 54.

Journal: Current oncology (Toronto, Ont.)
Published: June 25, 2026

Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond.

Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond.

Journal: Cancers
Published: June 15, 2026

Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01.

Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01.

Journal: Thoracic cancer
Published: June 03, 2026

Rare EGFRm NSCLC: More First-Line Options Emerge.

Rare EGFRm NSCLC: More First-Line Options Emerge.

Journal: Cancer discovery
Published: June 01, 2026

Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database.

Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database.

Journal: Investigational new drugs
Published: May 22, 2026

Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison.

Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison.

Journal: Frontiers in oncology
Published: May 17, 2026

Subcutaneous Amivantamab and Lazertinib in PALOMA-3: Efficacy, Safety, and Administration: A Vodcast.

Subcutaneous Amivantamab and Lazertinib in PALOMA-3: Efficacy, Safety, and Administration: A Vodcast.

Journal: Targeted oncology
Published: May 01, 2026

Strengthening the EGFR blockade for those lung cancers that need it most.

Strengthening the EGFR blockade for those lung cancers that need it most.

Journal: Translational lung cancer research
Published: April 27, 2026

Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian network meta-analysis with probabilistic multi-criteria decision analysis.

Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian network meta-analysis with probabilistic multi-criteria decision analysis.

Journal: Frontiers in immunology
Published: April 24, 2026

Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer.

Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 15, 2026
Showing 1-12 of 179

Last Updated: 09/26/2026